Inventor · disambiguated record
Suketu Sanghvi
Also filed as: SANGHVI SUKETU · SANGHVI SUKETU P
29 granted patents·21 pending applications·227 citations·filing 2004–2025
97Inventor score
Files withPAR PHARMACEUTICAL INC32PROGENICS PHARM INC5SCIENTURE INC5BOYD THOMAS A1OPTIMER PHARMACEUTICALS INC1
Top patents by PatentIndex Score
50 records- 0198US9375478B1Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2015·Granted Jun 28, 2016·24 cites·11 claims
- 0297US10624864B2Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2019·Granted Apr 21, 2020·8 cites·18 claims
- 0397US10010575B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Jul 3, 2018·8 cites·19 claims
- 0497US9981006B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted May 29, 2018·8 cites·19 claims
- 0597US9974827B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted May 22, 2018·8 cites·18 claims
- 0697US9968649B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted May 15, 2018·8 cites·17 claims
- 0797US9962422B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted May 8, 2018·8 cites·17 claims
- 0897US9925233B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Mar 27, 2018·8 cites·24 claims
- 0997US9919026B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Mar 20, 2018·9 cites·14 claims
- 1097US9750785B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Sep 5, 2017·16 cites·11 claims
- 1197US9744209B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Aug 29, 2017·15 cites·13 claims
- 1297US9687526B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2016·Granted Jun 27, 2017·16 cites·20 claims
- 1396US12280024B2Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2023·Granted Apr 22, 2025·1 cites·4 claims
- 1496US11135265B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2019·Granted Oct 5, 2021·4 cites·16 claims
- 1596US9993520B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Jun 12, 2018·6 cites·14 claims
- 1696US9925234B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Mar 27, 2018·6 cites·15 claims
- 1795US11207372B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2019·Granted Dec 28, 2021·3 cites·13 claims
- 1895US9937223B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2017·Granted Apr 10, 2018·6 cites·18 claims
- 1993US11337938B2Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2020·Granted May 24, 2022·2 cites·18 claims
- 2092US7563899B2(S)-N-methylnaltrexonePROGENICS PHARM INC·Filed 2006·Granted Jul 21, 2009·36 cites·19 claims
- 2189US8552025B2Stable methylnaltrexone preparationSANGHVI SUKETU P·Filed 2009·Granted Oct 8, 2013·13 cites·23 claims
- 2289US2024091176A1Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 2386US9669096B2Stable pharmaceutical formulations of methylnaltrexonePROGENICS PHARM INC·Filed 2013·Granted Jun 6, 2017·5 cites·39 claims
- 2484US12440458B2Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2022·Granted Oct 14, 2025·0 cites·20 claims
- 2584US12156869B2Losartan liquid formulations and methods of useSCIENTURE INC·Filed 2024·Granted Dec 3, 2024·1 cites·25 claims
- 2683US11890273B2Losartan liquid formulations and methods of useSCIENTURE INC·Filed 2022·Granted Feb 6, 2024·1 cites·20 claims
- 2783US10376584B2Stable pharmaceutical formulations of methylnaltrexonePROGENICS PHARM INC·Filed 2017·Granted Aug 13, 2019·2 cites·15 claims
- 2880US8003794B2(S)-N-methylnaltrexonePROGENICS PHARM INC·Filed 2009·Granted Aug 23, 2011·4 cites·12 claims
- 2977US2018133285A1Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3077US2018153955A1Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3176US2019105288A1Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3275US12186362B2Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2021·Granted Jan 7, 2025·0 cites·18 claims
- 3374US2023256048A1Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 3474US2018250245A1Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3573US2021077568A1Peptide congeners with polymer excipientsPAR PHARMACEUTICAL INC·Filed 2020·Application pending·0 cites
- 3672US2020188474A1Peptide congeners with polymer excipientsPAR PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3770US2017189352A1Epinephrine formulationsPAR PHARMACEUTICAL INC·Filed 2017·Application pending·0 cites
- 3869US2018185438A1Vasopressin formulations for use in treatment of hypotensionPAR PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3967US8916581B2(S)-N-methylnaltrexoneBOYD THOMAS A·Filed 2011·Granted Dec 23, 2014·1 cites·29 claims
- 4066US2019358328A1Stable pharmaceutical formulations of methylnaltrexonePROGENICS PHARM INC·Filed 2019·Application pending·0 cites
- 4158US2004266806A1Pharmaceutical formulationFiled 2004·Application pending·0 cites
- 4255US2008014257A1Oral dosage formsPAR PHARMACEUTICAL INC·Filed 2006·Application pending·0 cites
- 4351US2024033221A1Long-acting bupivacaine microsphere formulationsSCIENTURE INC·Filed 2021·Application pending·0 cites
- 4451US2008176927A1Compositions of stable tiacumicinsOPTIMER PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4548US2023137010A1Long-acting apomorphine formulations and injectors for therapeutic delivery of the sameSCIENTURE INC·Filed 2021·Application pending·0 cites
- 4646US2023043204A1Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the sameSCIENTURE INC·Filed 2020·Application pending·0 cites
- 4746US2004259899A1Combination therapy for constipationFiled 2004·Application pending·0 cites
- 4843US2025319070A1Losartan liquid formulations and methods of useSCIENTURE LLC·Filed 2025·Application pending·0 cites
- 4943US2005004155A1Use of methylnaltrexone to treat irritable bowel syndromeFiled 2004·Application pending·0 cites
- 5041US2013065844A1Compositions of Stable TiacumicinsSANGHVI SUKETU·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Suketu Sanghvi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →